Status:
COMPLETED
Ambulatory Oxygen for ILD
Lead Sponsor:
Anne Holland
Collaborating Sponsors:
The Alfred
Conditions:
Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
People with interstitial lung disease (ILD) are frequently prescribed ambulatory oxygen, to increase oxygen levels in the blood during daily activities. The best way of delivering this type of oxygen ...
Detailed Description
Exercise-induced hypoxaemia (EIA) is very common in individuals with ILD, due to progressive lung fibrosis which results in impaired gas exchange. It is common for people with EIA to be prescribed amb...
Eligibility Criteria
Inclusion
- a confident diagnosis of ILD made according to established criteria and
- desaturate to less than 90% during a 6-minute walk test
Exclusion
- primary diagnosis of a respiratory condition other than ILD (eg COPD)
- currently using continuous oxygen therapy
- oxyhaemoglobin saturation (SpO2) is less than 90% on room air
- unable to perform a 6-minute walk test or comorbidities that limit walking
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01906931
Start Date
August 1 2013
End Date
February 1 2014
Last Update
June 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3004